BELOIT—NorthStar Medical Technologies, LLC and Clarity Pharmaceuticals have signed a letter of intent for the commercial supply of copper-67 (Cu-67) as an active pharmaceutical ingredient for Clarity’s pipeline of copper-based radiopharmaceuticals.
Under terms of the agreement, NorthStar will provide Clarity Pharmaceuticals with Cu-67, a beta-emitting radioisotope with potential applications as a targeted radiopharmaceutical for treatment of a range of cancers. NorthStar will be a major U.S. supplier of Cu-67 for Clarity.
“NorthStar is committed to developing and commercializing innovative technologies for Cu-67 radioisotope production to advance medical research and meet patient needs,” said Stephen Merrick, President and Chief Executive Officer of NorthStar Medical Technologies.
NorthStar Medical Radioisotopes produces and distributes radioisotopes used for medical imaging and therapeutic purposes. Founded in 2006 and based in Beloit, NorthStar Medical Technologies is the parent organization of several wholly-owned subsidiaries, including NorthStar Medical Radioisotopes, LLC.
Clarity, based in Sydney, Australia, is a personalised medicine company focused on the treatment of serious diseases. The company is a leader in innovative radiopharmaceuticals, developing targeted therapies for the treatment of cancer and other serious diseases in adults and children.